Oliver’s notable representations include:
EQUITY AND EQUITY-LINKED
-
China Securities (International) Corporate Finance Company Limited and China Merchants Securities (HK) Co., Limited, as joint sponsors and overall coordinators, and the other underwriters in the Regulation S Hong Kong IPO of YH Entertainment Group. YH Entertainment is an established artist management company in China with the highest revenue-based market share according to Frost & Sullivan.
-
MicroPort NeuroTech Limited, a leading Chinese neuro-interventional medical device company, on its Rule 144A and Regulation S Hong Kong IPO. The listing is a spinoff from the Hong Kong–listed MicroPort Scientific Corporation.
-
Shanghai MicroPort MedBot (Group) Co., Ltd., the first Hong Kong–listed, globally top-tier surgical robot company, dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures, on its Rule 144A and Regulation S Hong Kong IPO pursuant to Chapter 18A of the Listing Rules. The listing is a spinoff from the Hong Kong–listed MicroPort Scientific Corporation.
-
Huatai and Credit Suisse, as joint sponsors, and the other underwriters in the Rule 144A and Regulation S Hong Kong IPO of China Youran Dairy Group Limited. Youran Dairy, previously a subsidiary of Yili, is a leader in China’s upstream dairy market.
- Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China, on its Rule 144A and Regulation S Hong Kong IPO pursuant to Chapter 18A of the Listing Rules. The listing is a spinoff from the Hong Kong-listed Lee’s Pharm Group.
- Suzhou Basecare Medical Corporation Limited, an innovative platform providing advanced genetic testing solutions of next generation sequencing technologies for assisted reproduction in China, on its Rule 144A and Regulation S Hong Kong IPO of H shares pursuant to Chapter 18A of the Listing Rules.
- Ocumension Therapeutics, a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies, on its Rule 144A and Regulation S Hong Kong IPO pursuant to Chapter 18A of the Listing Rules.
- Viva Biotech Holdings, a leading open-access and innovation-driven technology platform company, on its inaugural offering of US$180 million guaranteed convertible bonds due 2025 and subsequent offering of US$280 million guaranteed convertible bonds due 2025.
- Alphamab Oncology, a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering, on its Rule 144A and Regulation S Hong Kong IPO pursuant to Chapter 18A of the Listing Rules.
- CICC, Bank of America Merrill Lynch, CMB International, Fosun Hani and Citi, as joint sponsors, and the other underwriters in the Rule 144A and Regulation S H shares Hong Kong IPO of Shanghai Henlius Biotech, Inc. pursuant to Chapter 18A of the Listing Rules. Henlius is the first biopharmaceutical company to receive new drug application (NDA) approval from the National Medical Products Administration of the P.R.C. for a monoclonal antibody biosimilar in accordance with the Biosimilar Guidelines, the prevailing PRC regulation on biosimilar evaluation and marketing approval, and the first to commercially launch a biosimilar product in China. The listing is a dual-level spinoff from Hong Kong-listed Fosun International and A+H-listed Fosun Pharma.
- ManpowerGroup Greater China Limited, the largest workforce solutions provider in Greater China, on its Regulation S Hong Kong IPO. The transaction represents a carve-out from ManpowerGroup Inc., a New York Stock Exchange–listed world leader in workforce solutions and services.
- BabyTree Group, the largest and most active maternity and child-focused community platforms in China, on its Rule 144A and Regulation S Hong Kong IPO.
- Sunshine 100 China Holdings Ltd, a P.R.C.-based real estate developer, on its Rule 144A and Regulation S Hong Kong IPO.
- PanAsialum Holdings Company Limited, a P.R.C.-based aluminum products manufacturer most notably of unibody chassis of popular multimedia tablets, on its Rule 144A and Regulation S Hong Kong IPO.
- SouFun Holdings, Ltd., a leading real estate Internet portal in China, on its SEC-registered IPO (with ADSs) listed on the New York Stock Exchange.
DEBT, LIABILITY MANAGEMENT AND RESTRUCTURING
Over 130 Rule 144 A and Regulation S “high yield” debt offerings, including those conducted by:
- CAR Inc.*
- Guangzhou R&F
- Shimao Property
- Hilong Holding
- CIFI Holdings
- Modern Land China
- Longfor Properties*
- SOHO China
- China Oil & Gas Group
- China Logistics Property Holdings
(* as dedicated underwriters’ counsel)
Investment-grade, “cov lite” debt offerings by:
- Haidilao International Holding Limited, in its landmark debut offering of US$600 million 2.150% notes due 2026, the first global bond offering by a Chinese catering company
- Fosun International Limited, including, notably, the offering in 2019 of €400 million 4.35% senior notes due 2023, the first successful offering of its kind from the PRC private sector
- China Fortune Land Development
- Tingyi (Cayman Islands) Holding Corp.
- Golden Eagle Retail Group
Exchange and tender offers and consent solicitations by:
- Fosun International Limited
- Guangzhou R&F
- Hilong Holding
- Modern Land China
- China Fortune Land Development
- Kaisa Group
Restructuring by:
- Hilong Holding, through a scheme of arrangement in the Cayman Islands, of its offshore U.S. dollar–denominated notes. This complex transaction, which became effective on May 18, 2021, was the first completed offshore restructuring in the PRC oil and gas sector.
